Innophos Holdings, Inc. (IPHS) Given Average Recommendation of “Hold” by Brokerages
Innophos Holdings, Inc. (NASDAQ:IPHS) has been assigned an average broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.
Zacks has also given Innophos an industry rank of 159 out of 255 based on the ratings given to related companies.
A number of equities research analysts have recently issued reports on the company. TheStreet lowered Innophos from a “b-” rating to a “c+” rating in a research report on Thursday, August 23rd. BidaskClub lowered Innophos from a “hold” rating to a “sell” rating in a research report on Saturday, August 4th. Finally, Zacks Investment Research lowered Innophos from a “buy” rating to a “hold” rating in a research report on Thursday, July 5th.
Innophos (NASDAQ:IPHS) last announced its earnings results on Monday, July 30th. The specialty chemicals company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.10). The company had revenue of $206.73 million for the quarter, compared to analyst estimates of $213.40 million. Innophos had a return on equity of 14.28% and a net margin of 2.21%. The firm’s revenue for the quarter was up 15.4% on a year-over-year basis. During the same period last year, the firm earned $0.57 earnings per share. analysts expect that Innophos will post 2.79 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, September 5th. Stockholders of record on Friday, August 17th were given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 4.30%. The ex-dividend date of this dividend was Thursday, August 16th. Innophos’s dividend payout ratio (DPR) is presently 78.05%.
Several institutional investors have recently made changes to their positions in IPHS. Wells Fargo & Company MN raised its position in Innophos by 31.0% during the second quarter. Wells Fargo & Company MN now owns 238,344 shares of the specialty chemicals company’s stock valued at $11,345,000 after buying an additional 56,464 shares during the period. Neuberger Berman Group LLC raised its position in Innophos by 495.2% during the first quarter. Neuberger Berman Group LLC now owns 532,920 shares of the specialty chemicals company’s stock valued at $21,429,000 after buying an additional 443,390 shares during the period. FDx Advisors Inc. acquired a new position in Innophos during the first quarter valued at $350,000. Nisa Investment Advisors LLC raised its position in Innophos by 66.9% during the second quarter. Nisa Investment Advisors LLC now owns 6,235 shares of the specialty chemicals company’s stock valued at $297,000 after buying an additional 2,500 shares during the period. Finally, SG Americas Securities LLC raised its position in Innophos by 37.1% during the second quarter. SG Americas Securities LLC now owns 17,429 shares of the specialty chemicals company’s stock valued at $830,000 after buying an additional 4,721 shares during the period. 93.83% of the stock is currently owned by institutional investors.
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Recommended Story: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.